Marnie MacDonald has left Odyssey Thera, CBA News has learned. MacDonald was president and CEO of the company since 2002. Prior to that, MacDonald served as chief business officer for the company. Odyssey declined to comment on the reason for MacDonald's departure.
John Westwick is the current president and chief scientific officer, according to the company's website. It is unclear whether the company has named an interim or new CEO. Westwick joined Odyssey in 2003 as vice president of drug discovery.
CBA News has also learned that Dietrich Ruehlmann has left BD Biosciences and joined New Zealand Trade & Enterprise, a government organization that assists New Zealand biotechnology companies in commercial endeavours.
Ruehlmann was formerly product manager for imaging and analysis in the bioimaging systems division of BD Biosciences, based in Rockville, Md.
Invitrogen this week announced the availability of FISH Tag DNA and RNA kits, which enable a "complete workflow solution" for fluorescence in situ hybridization including all reagents needed for probe synthesis, labeling, purification, and imaging of labeled substances. FISH Tag kits are available in single-color kits with one of four Alexa Fluor dyes, or in multicolor kits with all four dyes to provide simultaneous localization of multiple sequence-specific RNA or DNA targets, Invitrogen said.
Invitrogen also said that it has instituted new functional labeling for Gibco cell culture products. The new labeling is designed to improve workflow through the addition of extra space for annotation, color coding for product identification, and inclusion of internationally recognized industry symbols for ease of storage and handling, Invitrogen said.
Asterand this week announced the availability of a cell line for breast cancer research. The MCF10DCIS.com cell line can be used for testing chemopreventive agents and for screening cancer-causing agents, as well as for screening anti-cancer drugs, Asterand said. The cell line is one set of a panel of MCF10 cell lines derived from normal mammary cells from a single patient that became spontaneously immortalized, Asterand said. The cells are being made available to commercial and academic researchers under an exclusive license from the Karmanos Cancer Institute at Wayne State University.